Expeck may be available in the countries listed below.
Ingredient matches for Expeck
Teprenone is reported as an ingredient of Expeck in the following countries:
- Japan
International Drug Name Search
Expeck may be available in the countries listed below.
Teprenone is reported as an ingredient of Expeck in the following countries:
International Drug Name Search
Class: Antidepressants, Miscellaneous
VA Class: CN609
Chemical Name: ±-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone Hydrochloride
Molecular Formula: C13H18ClNO•ClH
CAS Number: 31677-93-7
Brands: Wellbutrin, Zyban
Antidepressants may increase risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18–24 years of age) with major depressive disorder and other psychiatric disorders; balance this risk with clinical need.1 142 143 161 162 168 Bupropion is not approved for use in pediatric patients.1 142 143 168 (See Pediatric Use under Cautions.)
In pooled data analyses, risk of suicidality was not increased in adults >24 years of age and apparently was reduced in adults ≥65 years of age with antidepressant therapy compared with placebo.161 162
Depression and certain other psychiatric disorders are themselves associated with an increased risk of suicide.161 162 167
Appropriately monitor and closely observe all patients who are started on bupropion therapy for clinical worsening, suicidality, or unusual changes in behavior; involve family members and/or caregivers in this process.1 142 143 162 161 167 168 (See Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders under Cautions.)
Serious neuropsychiatric symptoms (e.g., depression, suicidal ideation, suicide attempt, completed suicide) have been reported in patients receiving bupropion for smoking cessation.182 183 184 185 186 187 (See Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment under Cautions.)
Symptoms have occurred in patients with and without preexisting psychiatric disease; some patients experienced worsening of their psychiatric illness.182 183 184 185
Depressed mood may be a symptom of nicotine withdrawal;182 183 184 185 186 however, some symptoms occurred in bupropion-treated patients who continued to smoke.182 183 184 185 186 187
Most symptoms occurred during bupropion therapy, but some were reported following discontinuance of drug.182 183 184 185
Monitor all patients receiving bupropion for smoking cessation for neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, and suicide-related events (including ideation, behavior, and attempted suicide).182 183 184 185
Patients should discontinue bupropion and immediately contact their clinician if agitation, hostility, depressed mood, or changes in thinking or behavior not typical for the patient occur, or if patient develops suicidal ideation or behavior.182 183 184 185
Symptoms resolved upon drug discontinuance in many cases, but persisted in a few cases.182 183 184 185 186 187 Provide ongoing monitoring and supportive care until symptoms resolve.182 183 184 185
Weigh risks of bupropion for smoking cessation against benefits.182 183 184 185 186 187 Bupropion shown to increase likelihood of abstinence from smoking for up to 6 months compared with placebo.182 183 184 185 186 187 Health benefits of quitting smoking are immediate and substantial.182 183 184 185 186 187
REMS:
FDA approved a REMS for bupropion to ensure that the benefits of a drug outweigh the risks. The REMS may apply to one or more preparations of bupropion and consists of the following: medication guide. See the FDA REMS page () or the ASHP REMS Resource Center ().
Antidepressant and smoking deterrent; aminoketone derivative.1 43 142 143 168
Treatment of major depressive disorder.1 127 128 129 131 132 142 168 179 180
May be useful (alone or in combination with other antidepressants) in patients with refractory depression.179 180
Prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD; also referred to as winter depression).168 169 170 171
Adjunct in the cessation of smoking (alone or in combination with nicotine replacement therapy).143 145 146 147 152 (See Cardiovascular Effects under Cautions and see also Smoking Cessation and Specific Drugs under Interactions.)
Treatment of patients with bipolar depression† (bipolar disorder, depressive episode).2 77 78 85 86 102 154
American Psychiatric Association (APA) considers bupropion one of several second-line agents for use when first-line agents are ineffective or not tolerated.154
Used in a limited number of children2 44 79 80 134 156 157 158 and adults in the management of ADHD†.2 44 76 126
Ineffective in the treatment of panic disorder and concomitant phobic disorder†,2 44 99 134 but may improve symptoms of panic and depression in patients with major depression who have superimposed panic symptoms.44
Not recommended by APA for bulimia nervosa† because associated with seizures in purging bulimic patients.153
Appropriately monitor and closely observe all patients receiving bupropion for any indication for clinical worsening, suicidality, or unusual changes in behavior, particularly during initial therapy or following any change (increase or decrease) in dosage.161 162 167 182 183 184 (See Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders in Boxed Warning and also under Cautions.)
Monitor all patients receiving bupropion for smoking cessation for serious neuropsychiatric symptoms or worsening of preexisting psychiatric illness.182 183 184 185 186 187 (See Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment in Boxed Warning and also under Cautions.)
Increase dosages gradually to minimize the risk of seizures and other adverse effects; do not exceed recommended maximum individual doses or daily dosages.1 142 168 (See Prescribing Limits and see Seizures under Warnings.)
Maximum antidepressant effects of therapy may not be evident until ≥4 weeks of treatment.1 142 168
Sustained therapy may be required; monitor periodically for need for continued therapy.1 142 168
Initially, administer orally twice daily in the morning and evening, then increase to 3 times daily, preferably with 6 or more hours separating doses (e.g., in the morning, at midday, and in the evening).1 23 24 141
Dosages ≥300 mg should be administered as divided doses that do not exceed 150 mg per dose.1 If components of a larger dosage include 4 whole tablets of 100 mg each, administer the divided doses 4 times daily separated by 4 or more hours so that no individual dose exceeds 150 mg.1
Avoid bedtime administration of evening dose to decrease incidence of insomnia.1 142 152
Extended-release, film-coated tablets (e.g., Wellbutrin SR): Initially, administer orally once daily in the morning, then increase to twice daily, in the morning and evening.142 Dosages >150 mg should be administered as divided doses twice daily, preferably with 8 or more hours separating the doses.142 143 Avoid bedtime administration of evening dose to decrease incidence of insomnia.183
Extended-release, film-coated tablets (e.g., Zyban): Administer orally once daily for the first 3 days, then usually increase to twice daily administration with 8 or more hours separating the doses.143 Avoid bedtime administration of evening dose to decrease incidence of insomnia.182
Extended-release tablets (Wellbutrin XL): Administer orally once daily in the morning, with an interval of 24 hours separating the doses.168
Do not chew, divide, or crush the extended-release tablets (e.g., Zyban, Wellbutrin SR, Wellbutrin XL); tablets should be swallowed whole.142 143 168
The shell of the extended-release tablet (Wellbutrin XL) does not dissolve and may be passed in the stool.168
Available as bupropion hydrochloride; dosage expressed in terms of the salt.1
Children weighing ≥20 kg: Initially, 1 mg/kg daily in 2–3 divided doses.156 After 3 days, titrate up to 3 mg/kg daily in 2–3 divided doses by day 7, then up to 6 mg/kg daily in 2–3 divided doses or 300 mg (whichever is smaller) by third week of therapy.156
Alternatively, may give initial dose of 37.5 or 50 mg twice daily with titration over 2 weeks up to a maximum of 250 mg daily (300–400 mg daily in adolescents).157
Pediatric dosage for ADHD generally has ranged from 50–100 mg 3 times daily for conventional tablets or 100–150 mg twice daily for extended-release tablets.158
Initially, 100 mg twice daily.1 Alternatively, dosage may be initiated at 75 mg 3 times daily.23 24 141
If clinical improvement not apparent after >3 days, may increase to 100 mg 3 times daily.1 23 24 141 142
Dosages >300 mg should not be considered until completion of several weeks of therapy; if no improvement is apparent, then the dosage may be increased to 150 mg 3 times daily.1 142 Dosage should not be increased by more than 100 mg every 3 days.1 23 24 141 142
If no improvement after appropriate trial at 450 mg daily, the drug should be discontinued.1 23 24 141
Extended-release, film-coated tablets (e.g., Wellbutrin SR): Initially, 150 mg once daily in the morning.142 If tolerated, may increase to 150 mg twice daily as early as fourth day of therapy.142 Dosages >300 mg daily should not be considered until completion of several weeks of therapy; then, if no apparent improvement, may increase dosage to 200 mg twice daily.1 142
Extended-release tablets (Wellbutrin XL): Initially, 150 mg once daily.168 If tolerated, may increase to 300 mg once daily as early as fourth day of therapy.168 Dosages >300 mg should not be considered until completion of several weeks of therapy; then, if no apparent improvement, may increase dosage to 450 mg once daily.168
When switching from conventional or extended-release, film-coated tablets (e.g., Wellbutrin SR) to extended-release tablets (Wellbutrin XL), administer same total daily dose when possible.168
Extended-release tablets (Wellbutrin XL): Initiate therapy in autumn prior to onset of depressive symptoms; continue treatment through the winter and taper and discontinue in early spring.168 169 Individualize timing of initiation and duration of therapy based on patient’s historical pattern of seasonal depressive episodes.168
Initially, 150 mg once daily in the morning.168 If tolerated, may increase dosage after 1 week to 300 mg once daily.168 If this dosage is not tolerated, reduce dosage to 150 mg once daily.168
Usual target dosage: 300 mg once daily in the morning.168
For patients receiving 300 mg once daily during the autumn-winter period, taper dosage to 150 mg once daily for 2 weeks prior to discontinuance.168
Initially, 150 mg daily for the first 3 days of therapy.143 145 152 Initiate 1–2 weeks prior to discontinuance of cigarette smoking.143 145 152
Maintenance, 150 mg twice daily.143 145 Continue therapy for 7–12 weeks; evaluate need for prolonged therapy after that period based on individual patient assessment.143 152
Cessation of smoking is unlikely in patients who do not show substantial progress toward abstinence after 7 weeks of therapy, so such therapy should be discontinued at that time in these patients.143
Initially, 150 mg daily, and after 3 days increase to 150 mg twice daily while still smoking.143
After about 1 week of therapy, when the patient is scheduled to stop smoking, initiate transdermal nicotine therapy at a dosage of 21 mg/24 hours.143
Taper transdermal nicotine to 14, then to 7 mg/24 hours during the eighth and ninth weeks of therapy, respectively.143
Dosages generally range from 75–400 mg in conjunction with a mood-stabilizing agent (e.g., carbamazepine, lithium, valproate).2
Initially, 150 mg daily.2 May be titrated up to 450 mg daily.2
Conventional tablets: Maximum 450 mg daily (not >150 mg per dose).1
Extended-release, film-coated tablets (e.g., Wellbutrin SR): Maximum 400 mg daily (not >200 mg per dose).142
Extended-release tablets (Wellbutrin XL): Maximum 450 mg daily.168
Extended-release tablets (e.g., Wellbutrin XL): Dosages >300 mg daily have not been studied.168
Extended-release, film-coated tablets (e.g., Zyban): 300 mg daily (not >150 mg per dose).143
Dosage Form | Maximum Dosage |
---|---|
Conventional tablets | 75 mg once daily1 |
Extended-release, film-coated tablets (e.g., Wellbutrin SR) | 100 mg once daily or 150 mg every other day142 |
Extended-release tablets (Wellbutrin XL) | 150 mg every other day168 |
Smoking cessation in patients with severe hepatic cirrhosis: Maximum 150 mg every other day as extended-release, film-coated tablets (e.g., Zyban).143
Major depression, seasonal affective disorder, or smoking cessation in patients with mild to moderate hepatic impairment (e.g., mild to moderate hepatic cirrhosis): Reduce dosage and/or frequency of administration as required.1 142 143 168 (See Hepatic Impairment under Cautions.)
Active metabolites may accumulate; reduce dosage and/or frequency of administration as required.1 142 143 168 177 (See Renal Impairment under Cautions.)
Smoking cessation in patients undergoing hemodialysis: Some clinicians recommend a dosage of 150 mg every 3 days as extended-release, film-coated tablets (e.g., Zyban).177
Seizure disorders.1 142 143 152 168
Current or past diagnosis of anorexia nervosa or bulimia.1 21 22 24 39 142 143 152 168
Contraindicated in patients receiving any other bupropion formulation (e.g., for smoking cessation, antidepressant use) because risk of seizures is dose-dependent.1 142 143 168
Patients undergoing abrupt discontinuance of alcohol or sedatives (including benzodiazepines).1 142 143 168
Patients currently receiving, or having recently received (i.e., within 2 weeks), MAO inhibitor therapy.1 142 152 168
Hypersensitivity to the drug or any ingredient in the formulation.1 142 168
Seizures reported;1 6 19 20 24 52 142 143 168 risk of seizures may be higher with sudden and large increases in dosage.1 8 (See Dosage and Administration.)
Risk factors include patient factors (e.g., history of head trauma or prior seizure, CNS tumor, presence of severe hepatic cirrhosis), clinical situations (excessive use of alcohol or sedatives [e.g., benzodiazepines], abrupt withdrawal from alcohol or other sedatives, addiction to opiates, cocaine, or stimulants, use of OTC stimulants and anorectics, diabetes treated with oral hypoglycemics or insulin), and concomitant drugs that lower seizure threshold.1 8 142 143 168 (See Interactions: Specific Drugs.)
If patients experience a seizure during therapy, discontinue drug and do not restart.1 142 143 168
Possible worsening of depression and/or emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior in both adult and pediatric patients with major depressive disorder, whether or not they are taking antidepressants; may persist until clinically important remission occurs.1 142 143 161 162 167 168 181 However, suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.161 162 167
Appropriately monitor and closely observe patients receiving bupropion for any reason, particularly during initiation of therapy (i.e., the first few months) and during periods of dosage adjustments.1 142 143 161 162 167 168 (See Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders in Boxed Warning and also see Pediatric Use under Cautions.)
Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and/or mania may be precursors to emerging suicidality.161 167 Consider changing or discontinuing therapy in patients whose depression is persistently worse or in those with emerging suicidality or symptoms that might be precursors to worsening depression or suicidality, particularly if severe, abrupt in onset, or not part of patient’s presenting symptoms.1 142 143 161 162 167 168 (See General under Dosage and Administration.)
Prescribe in smallest quantity consistent with good patient management to reduce risk of overdosage.1 142 143 168 161
Observe these precautions for patients with psychiatric (e.g., major depressive disorder, obsessive-compulsive disorder) or nonpsychiatric disorders.1 142 143 161 168
Serious neuropsychiatric symptoms, including mood changes (e.g., depression, mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety, and panic as well as suicidal ideation, suicide attempt, and completed suicide, reported in patients receiving bupropion for smoking cessation.182 183 184 185 186 187 (See Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment in Boxed Warning.)
Monitor all patients receiving bupropion for smoking cessation for such neuropsychiatric symptoms.182 183 184 185
Patients and caregivers that patients should stop taking bupropion and immediately contact their clinician if agitation, hostility, depressed mood, or changes in thinking or behavior not typical for the patient occur, or if patient develops suicidal ideation or behavior.182 183 184 185 Symptoms resolved upon drug discontinuance, in many cases but persisted in a few cases.182 183 184 185 186 187 Provide ongoing monitoring and supportive care until symptoms resolve.182 183 184 185 186
Weigh possible risk of serious adverse effects with bupropion against health benefits of smoking cessation (e.g., reduced risk of developing pulmonary disease, cardiovascular disease, and cancer).182 183 184 185 186 187
May unmask bipolar disorder.1 142 143 161 168 (See Activation of Mania or Psychosis under Cautions.) Bupropion is not approved for use in treating bipolar depression.1 142 143 168
Screen for risk of bipolar disorder by obtaining detailed psychiatric history (e.g., family history of suicide, bipolar disorder, depression) prior to initiating therapy.1 142 143 161 168
Anaphylactoid reactions (e.g., pruritus, urticaria, angioedema, dyspnea) have been reported;1 142 143 168 however, causality has not been established.145 Postmarketing reports include erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock.1 142 143 168
Possible arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity.1 142 143 168
Abnormal hepatic function (e.g., jaundice, hepatitis) infrequently reported during postmarketing surveillance; causal relationship not established.1 40 142 143 168 However, increased incidence of hepatic hyperplastic nodules and hepatocellular hypertrophy observed in rats receiving large doses and various histologic changes and mild hepatocellular injury observed in dogs administered large doses of the drug.1 142 143 168
Agitation,1 3 5 6 7 8 45 46 47 51 52 53 54 142 168 insomnia,1 3 5 7 45 46 47 51 52 53 142 143 152 168 and anxiety1 3 54 142 168 have been reported.1 Insomnia may be minimized by avoidance of bedtime administration or reduction of dosage.1 142 143 168
Neuropsychiatric manifestations, including confusion, delusions, hallucinations, psychosis, disturbances in concentration, and paranoia, reported in patients receiving bupropion in depression trials.182 183 184 185 Similar types of neuropsychiatric manifestations reported during postmarketing experience in patients receiving the drug for smoking cessation.182 183
Possible activation of mania or hypomania in bipolar disorder patients (see Bipolar Disorder under Cautions); activation of latent psychosis may occur in susceptible patients.1 142 143 168
Possible anorexia and weight loss (exceeding 2.27 kg);1 19 29 30 52 caution in patients in whom weight loss is a presenting manifestation of depression.1 143 168
Hypertension (sometimes severe) has occurred with bupropion therapy either alone or in combination with transdermal nicotine in patients with and without pre-existing hypertension.1 Safety in patients with recent history of MI or unstable heart disease not established.1 142 143 168
Possible increased duration of motor and EEG seizures in certain patients.44 94 104 Some clinicians suggest that ECT can be safely performed 48 hours after discontinuance of bupropion.44
Category B.1 142 143 168 Bupropion pregnancy registry at 800-336-2176.1 142 143 168
Distributed into milk; discontinue nursing or drug.1 2 64 142 143 168
Safety and efficacy not established in children <18 years of age.1 142 143 168
FDA warns that a greater risk of suicidal thinking or behavior (suicidality) occurred during first few months of antidepressant treatment compared with placebo in children and adolescents with major depressive disorder, obsessive-compulsive disorder (OCD), or other psychiatric disorders based on pooled analyses of 24 short-term, placebo-controlled trials of 9 antidepressant drugs (SSRIs and others).1 142 143 161 162 168 However, a more recent meta-analysis of 27 placebo-controlled trials of 9 antidepressants (SSRIs and others) in patients <19 years of age with major depressive disorder, OCD, or non-OCD anxiety disorders suggests that the benefits of antidepressant therapy in treating these conditions may outweigh the risks of suicidal behavior or suicidal ideation.181 No suicides occurred in these pediatric trials.1 142 143 161 162 168 181
Carefully consider these findings when assessing potential benefits and risks of bupropion in a child or adolescent for any clinical use.1 142 143 162 168 162 161 167 181 (See Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders in Boxed Warning and also under Cautions.)
Has been used in a limited number of children 7–16 years of age for attention deficit disorder† without unusual adverse effect.2 44 79 80 134 158
Has been used as extended-release preparation in adolescents for smoking cessation†.152 (See Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment in Boxed Warning and also under Cautions.)
Use with caution;1 possible decreased clearance.1 142 143 No substantial differences in safety and efficacy relative to younger adults.1 2 142 143 168
In pooled data analyses, a reduced risk of suicidality was observed in adults ≥65 years of age with antidepressant therapy compared with placebo.162 161 (See Clinical Worsening and Suicide Risk in Treating Psychiatric Disorders in Boxed Warning and also under Cautions.)
Use with extreme caution in patients with severe hepatic cirrhosis and caution in patients with hepatic impairment (e.g., mild to moderate hepatic cirrhosis); reduced frequency and/or dosage and close monitoring for adverse effects required.1 142 143 168 (See Hepatic Impairment under Dosage and Administration.)
Use with caution; active metabolites may accumulate.1 142 143 168 177 Monitor closely for adverse effects (e.g., seizures); reduction in dosage and/or frequency may be necessary.1 142 143 168 177
Agitation, dry mouth, insomnia, headache/migraine, nausea/vomiting, constipation, tremor.1 3 6 7 19 44 47 50 134 142 143 152 168
Metabolized principally by CYP2B6; may also inhibit CYP2D6 and induce other hepatic microsomal enzymes.1 142 143 168
Potential pharmacokinetic interaction (altered serum concentrations of bupropion) with drugs that induce or inhibit CYP2B6.1 142 143 168
Substrates of CYP2D6: potential pharmacokinetic interaction (increased plasma substrate concentrations).1 142 143 168
Substrates of hepatic microsomal enzymes: potential pharmacokinetic interaction (altered substrate metabolism).1 142 143 168
Smoking may induce enzymes and increase metabolism of some drugs.149 150 151 Therefore, cessation of smoking (with or without adjunctive use of bupropion) may result in decreased enzyme induction and altered metabolism of some drugs (e.g., theophylline, warfarin); consider dosage adjustment.143
Drug | Interaction | Comments |
---|---|---|
Alcohol | Possible neuropsychiatric effects or reduced alcohol tolerance1 142 143 Possible increased risk of seizures with excessive use of alcohol or abrupt withdrawal from alcohol1 142 143 | Minimize or avoid alcohol consumption 1 142 143 168 |
Amantadine | Potential increased incidence of adverse |
Generic Name: omalizumab (OH ma LIZ oo mab)
Brand Names: Xolair
Omalizumab is an antibody that helps decrease allergic responses in the body.
Omalizumab is used to treat moderate to severe asthma that is caused by allergies in adults and children who are at least 12 years old.
Omalizumab is usually given after other asthma medications have been tried without successful treatment of symptoms.
Omalizumab may also be used for purposes not listed in this medication guide.
Get emergency medical help if you have any of these signs of an allergic reaction: wheezing, tightness in your chest, trouble breathing; hives or skin rash; feeling anxious or light-headed, fainting; warmth or tingling under your skin; or swelling of your face, lips, tongue, or throat.
Asthma is often treated with a combination of different drugs. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.
Use omalizumab regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
To make sure you can safely take omalizumab, tell your doctor if you have any other medical conditions or if you take other medicines.
While you are using omalizumab, you may also have an increased risk of becoming infected with parasites (worms) if you live in or travel to areas where such infections are common. Talk with your doctor about what to look for and how to treat this condition.
If you are pregnant, your name may be listed on a pregnancy registry. This is to track the outcome of the pregnancy and to evaluate any effects of omalizumab on the baby.
Omalizumab is injected under the skin. You may be shown how to use injections at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles and syringes.
Omalizumab is usually given every 2 or 4 weeks.
Omalizumab is a powder medicine that must be mixed with a liquid (diluent) before using it. If you are using the injections at home, be sure you understand how to properly mix and store the medication.
Use a disposable needle only once. Throw away used needles in a puncture-proof container (ask your pharmacist where you can get one and how to dispose of it). Keep this container out of the reach of children and pets.
Asthma is often treated with a combination of different drugs. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.
Use omalizumab regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
To be sure this medication is helping your condition, your doctor may want you to have allergy tests and lung function tests on a regular basis. Do not miss any scheduled visits to your doctor.
Contact your doctor if you miss a dose of omalizumab.
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Get emergency medical help if you have any of these signs of an allergic reaction:
wheezing, tightness in your chest, trouble breathing;
hives or skin rash;
feeling anxious or light-headed, fainting;
warmth or tingling under your skin; or
swelling of your face, lips, tongue, or throat.
Other serious side effects include easy bruising or bleeding, numbness, or unusual weakness.
Less serious side effects may include:
pain;
headache, tired feeling;
joint or muscle pain;
dizziness;
ear pain;
hair loss;
mild itching or skin rash;
sore throat or cold symptoms; or
redness, bruising, warmth, burning, stinging, itching, pain, or swelling of your skin where the injection was given.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Asthma -- Maintenance:
150 to 300 mg subcutaneously every 4 weeks or 225 to 375 mg every 2 weeks, depending on pretreatment IgE levels and patient's weight.
30 to 60 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 150 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >300 to 400 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >400 to 500 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >500 to 600 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >600 to 700 intl units/mL give 375 mg subcutaneously every 2 weeks.
60 to 70 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 150 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >300 to 400 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >400 to 500 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >500 to 600 intl units/mL give 375 mg subcutaneously every 2 weeks.
Do not dose if the patient has an IgE level >600 intl units/mL.
70 to 90 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 150 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >300 to 400 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >400 to 500 intl units/mL give 375 mg subcutaneously every 2 weeks.
Do not dose if the patient has an IgE level >500 intl units/mL.
>90 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 300 mg subcutaneously every 2 weeks.
Do not dose if the patient has an IgE level >300 intl units/mL.
Usual Pediatric Dose for Asthma -- Maintenance:
>=12 years: 150 to 300 mg subcutaneously every 4 weeks or 225 to 375 mg every 2 weeks, depending on pretreatment IgE levels and patient weight.
30 to 60 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 150 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >300 to 400 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >400 to 500 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >500 to 600 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >600 to 700 intl units/mL give 375 mg subcutaneously every 2 weeks.
60 to 70 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 150 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >300 to 400 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >400 to 500 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >500 to 600 intl units/mL give 375 mg subcutaneously every 2 weeks.
Do not dose if the patient has an IgE level >600 intl units/mL.
70 to 90 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 150 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >300 to 400 intl units/mL give 300 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >400 to 500 intl units/mL give 375 mg subcutaneously every 2 weeks.
Do not dose if the patient has an IgE level >500 intl units/mL.
>90 kg:
If the patient has an IgE level of >=30 to 100 intl units/mL give 300 mg subcutaneously every 4 weeks.
If the patient has an IgE level of >100 to 200 intl units/mL give 225 mg subcutaneously every 2 weeks.
If the patient has an IgE level of >200 to 300 intl units/mL give 300 mg subcutaneously every 2 weeks.
Do not dose if the patient has an IgE level >300 intl units/mL.
Before using omalizumab, tell your doctor if you are receiving allergy shots.
There may be other drugs that can interact with omalizumab. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: omalizumab side effects (in more detail)
Norzac may be available in the countries listed below.
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Norzac in the following countries:
International Drug Name Search
Fénofibrate CristerS may be available in the countries listed below.
Fenofibrate is reported as an ingredient of Fénofibrate CristerS in the following countries:
International Drug Name Search
Treating infections caused by certain bacteria.
Doripenem is a carbapenem antibiotic. It works by killing sensitive bacteria.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Doripenem. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Doripenem. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Doripenem may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Doripenem as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Doripenem.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Headache; mild diarrhea; nausea.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody stools; chest pain; pain, swelling, or redness at the injection site; red, swollen, blistered, or peeling skin; seizures; severe diarrhea; severe stomach cramps or pain; shortness of breath; unusual tiredness or weakness; unusual vaginal odor, itching, or discharge.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Doripenem side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Doripenem is usually handled and stored by a health care provider. If you are using Doripenem at home, store Doripenem as directed by your pharmacist or health care provider. Keep Doripenem out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Doripenem. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Ferro Gluconato Sinclair may be available in the countries listed below.
Ferrous Gluconate is reported as an ingredient of Ferro Gluconato Sinclair in the following countries:
International Drug Name Search
Trifosfaneurina may be available in the countries listed below.
Thiamine phosphate (a derivative of Thiamine) is reported as an ingredient of Trifosfaneurina in the following countries:
International Drug Name Search
Memodrin may be available in the countries listed below.
Aniracetam is reported as an ingredient of Memodrin in the following countries:
International Drug Name Search